10 results about "Temozolomide" patented technology

This invention provides a combination for use in treating cancers that express prostate-specific membrane antigen (PSMA). [Solution] A combination comprising a PD-1 inhibitor, a CTLA-4 inhibitor, and a radiolabeled compound of formula Ia for use in treating PSMA-expressing cancer in the subject. JPEG2026049728000042.jpg45132 The aforementioned combination comprises one or more further anticancer agents, wherein the further anticancer agents are selected from octreotide, lanreotide, vapreotide, pasireotide, satreotide, everolimus, temozolomide, telotristat, sunitinib, sulfatinib, ribociclib, entinostat, and pazopanib.

The application discloses application of a swertianol derivative in preparation of a glioma treatment drug and belongs to the technical field of medicines. The application finds that the compound has significant inhibitory activity on SF126, T98G, A172, U-87 MG, U251 and various glioma cell lines, and the activity is better than that of temozolomide, a commonly used clinical anti-glioma drug, and the compound has lower toxicity to normal brain cells. The application further provides a preparation method of the compound and a pharmaceutical composition containing the compound, and the pharmaceutical composition can be prepared into injection, tablets and various dosage forms. The application provides a new effective drug selection for the treatment of glioma, has a mature preparation process, various drug dosage forms and a wide clinical application prospect.

The invention discloses application of carabrone derivatives in preparation of glioma drugs, and belongs to the technical field of medicines. It is found for the first time that the compound has remarkable inhibitory activity on multiple glioma cell lines such as SF126, T98G, A172, U-87 MG and U251, the activity of the compound is superior to that of temozolomide which is a clinically common anti-glioma drug, and meanwhile the compound is low in toxicity to normal brain cells. The invention also provides a preparation method of the compound and a pharmaceutical composition containing the compound. The pharmaceutical composition can be prepared into various dosage forms such as injections, tablets and the like. The invention provides a new effective drug choice for the treatment of glioma, and has the advantages of mature preparation process, various dosage forms and wide clinical application prospect.

The application discloses a targeted drug for treating glioma and a preparation method and application thereof. Alkaline copper carbonate, dopamine hydrochloride and ammonia water are mixed and dissolved, then defatted cotton is added, stirring is conducted until the defatted cotton is dissolved, and copper ammonia fiber solution is obtained by reaction at room temperature; a mixed solution of soluble copper ion salt, zinc ion salt and cobalt ion salt is prepared as a metal ion acid bath solution; the copper ammonia fiber solution is slowly injected into the metal ion acid bath solution, stirring reaction is completed, and then centrifugal separation is conducted; the obtained precipitate is added into a temozolomide solution, ultrasonic treatment is conducted under ice bath, and then centrifugal separation is conducted to obtain a precipitate; the precipitate is washed and freeze-dried to obtain polydopamine modified temozolomide adsorbed copper ammonia fiber; finally, the obtained polydopamine modified temozolomide adsorbed copper ammonia fiber is added into phosphate buffer solution containing Anti-ATRX antibody for incubation, and then washing, freeze-drying and grinding are conducted to obtain the product.

The invention relates to a method for modifying Mg-Al layered double hydroxide drug-loaded particles by a one-step method, which comprises the following steps: preparing wet Mg-Al layered double hydroxide by hydrothermal reaction, preparing a sulfydryl modifier, and adding a modification solution into the wet Mg-Al layered double hydroxide for modification to obtain the modified Mg-Al layered double hydroxide. And then adding temozolomide to obtain the Mg-Al layered double hydroxide medicine carrying material. The Mg-Al layered double hydroxide is modified by adopting a trimercaptopropylmethoxysilane one-step method, the operation is simple, the experimental environment is not complicated, the controllability in the reaction process is good, and the modified Mg-Al layered double hydroxide has relatively high drug loading capacity.

Disclosed is a method for treating a condition, which includes the steps of: selecting a patient for treatment who has the condition; administering to the patient at least one active pharmaceutical ingredient (API); and administering to the patient at least one metal complex represented by formula (I):including hydrates, solvates, pharmaceutically acceptable salts and prodrugs thereof. Also disclosed is a composition for conducting the method, which includes: at least one API selected from the group consisting of Cisplatin, Temozolomide, Vandetanib, Withaferin A, Vemurafenib, Amiodarone, Vinblastine, Metformin, Gemcitabine and Acyclovir; and at least one metal complex effective to potentiate an efficacy of the API to treat the condition, wherein the at least one metal complex is represented by formula (I), including hydrates, solvates, pharmaceutically acceptable salts and prodrugs thereof.

The invention discloses an application of a 3-fluoroalkyl quinoxalinone derivative in preparation of anti-glioma drugs, and belongs to the technical field of medicines. The 3-fluoroalkyl quinoxalinone derivative has excellent anti-glioma activity, especially has a remarkable inhibition effect on glioma Glioma 261 cells, the inhibition effect of the 3-fluoroalkyl quinoxalinone derivative is remarkably superior to that of temozolomide which is widely applied at present, and the 3-fluoroalkyl quinoxalinone derivative has good development value and wide application prospects.

Provided herein are methods of treating a cancer in a subject, and methods of improving responsiveness of a subject to a cancer therapy. Also provided herein is tigilanol tiglate and pharmaceutical compositions thereof for use in such methods, and uses of tigilanol tiglate and pharmaceutical compositions thereof for treating cancer and improving responsiveness to a subsequent cancer therapy, such as immune checkpoint inhibitors, gemcitabine, docetaxel, or temololomide.

The invention belongs to the technical field of medicines, and particularly relates to a sound-sensitive agent and a preparation method and application thereof, and the sound-sensitive agent has a structure as shown in a formula (I), methacrylate-temozolomide (MA-TMZ) has good sound sensitivity and blood brain barrier penetrability, and ultrasonic and MA-TMZ can induce generation of singlet oxygen so as to enhance the toxic effect of the medicine on brain glioma and melanoma cells. The new therapy for developing the anti-tumor effect by utilizing sonodynamic development of MA-TMZ and active products through ultrasonic excitation has immeasurable clinical application value.

The invention relates to the technical field of biology, and discloses a nano-composite and a preparation method and application thereof, the nano-composite is used for realizing diagnosis and treatment integration of glioblastoma, and the nano-composite comprises nanogel, nano-particles loaded with ultra-small Fe3O4, temozolomide and PD-L1siRNA. The preparation process of the nano material is relatively easy, and the USIO NGs-TMZ / siRNA compound is relatively stable in vivo, so that the loaded gene can be prevented from being degraded by enzyme in vivo in the transportation process, the siRNA is promoted to realize rapid endosome escape, and the tumor treatment effect is enhanced.